The global leukemia inhibitory factor (LIF) market size is calculated at USD 1.34 billion in 2025 and is forecasted to reach around USD 2.90 billion by 2034, accelerating at a CAGR of 8.94% from 2025 to 2034. The North America market size surpassed USD 500 million in 2024 and is expanding at a CAGR of 9.15% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Leukemia Inhibitory Factor (LIF) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Leukemia Inhibitory Factor (LIF) Market Revenue and Volume, by Product Type
8.1.1 Recombinant LIF
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. LIF Antibodies
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. LIF Receptor Agonists/Antagonists
8.1.3.1. Market Revenue and Volume Forecast
9.1. Leukemia Inhibitory Factor (LIF) Market Revenue and Volume, by Application
9.1.1. Cancer Treatment
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Stem Cell Research
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Neurological Disorders
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Fertility Treatment
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Volume Forecast
10.1. Leukemia Inhibitory Factor (LIF) Market Revenue and Volume, by End-User
10.1.1. Hospitals
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Research Institutes
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Biotechnology Companies
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product Type
11.1.2. Market Revenue and Volume Forecast, by Application
11.1.3. Market Revenue and Volume Forecast, by End-User
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product Type
11.1.4.2. Market Revenue and Volume Forecast, by Application
11.1.4.3. Market Revenue and Volume Forecast, by End-User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product Type
11.1.5.2. Market Revenue and Volume Forecast, by Application
11.1.5.3. Market Revenue and Volume Forecast, by End-User
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product Type
11.2.2. Market Revenue and Volume Forecast, by Application
11.2.3. Market Revenue and Volume Forecast, by End-User
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product Type
11.2.4.2. Market Revenue and Volume Forecast, by Application
11.2.4.3. Market Revenue and Volume Forecast, by End-User
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product Type
11.2.5.2. Market Revenue and Volume Forecast, by Application
11.2.5.3. Market Revenue and Volume Forecast, by End-User
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product Type
11.2.6.2. Market Revenue and Volume Forecast, by Application
11.2.6.3. Market Revenue and Volume Forecast, by End-User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product Type
11.2.7.2. Market Revenue and Volume Forecast, by Application
11.2.7.3. Market Revenue and Volume Forecast, by End-User
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product Type
11.3.2. Market Revenue and Volume Forecast, by Application
11.3.3. Market Revenue and Volume Forecast, by End-User
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product Type
11.3.4.2. Market Revenue and Volume Forecast, by Application
11.3.4.3. Market Revenue and Volume Forecast, by End-User
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product Type
11.3.5.2. Market Revenue and Volume Forecast, by Application
11.3.5.3. Market Revenue and Volume Forecast, by End-User
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product Type
11.3.6.2. Market Revenue and Volume Forecast, by Application
11.3.6.3. Market Revenue and Volume Forecast, by End-User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product Type
11.3.7.2. Market Revenue and Volume Forecast, by Application
11.3.7.3. Market Revenue and Volume Forecast, by End-User
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product Type
11.4.2. Market Revenue and Volume Forecast, by Application
11.4.3. Market Revenue and Volume Forecast, by End-User
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product Type
11.4.4.2. Market Revenue and Volume Forecast, by Application
11.4.4.3. Market Revenue and Volume Forecast, by End-User
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product Type
11.4.5.2. Market Revenue and Volume Forecast, by Application
11.4.5.3. Market Revenue and Volume Forecast, by End-User
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product Type
11.4.6.2. Market Revenue and Volume Forecast, by Application
11.4.6.3. Market Revenue and Volume Forecast, by End-User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product Type
11.4.7.2. Market Revenue and Volume Forecast, by Application
11.4.7.3. Market Revenue and Volume Forecast, by End-User
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product Type
11.5.2. Market Revenue and Volume Forecast, by Application
11.5.3. Market Revenue and Volume Forecast, by End-User
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product Type
11.5.4.2. Market Revenue and Volume Forecast, by Application
11.5.4.3. Market Revenue and Volume Forecast, by End-User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product Type
11.5.5.2. Market Revenue and Volume Forecast, by Application
11.5.5.3. Market Revenue and Volume Forecast, by End-User
12.1. Bristol Myers Squibb
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. InVitria
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Johnson & Johnson Private Limited
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Gilead Sciences Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Sanofi S.A.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Novartis AG
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Roche
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Amgen Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck KGaA
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client